Finding effective cancer therapies through loss of function genetic screens

Current Opinion in Genetics and Development

Volumn 24, Issue 1, 2014, Pages 23-29

  Bernards, René ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NAVITOCLAX; RETINOIC ACID; SELUMETINIB; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

BREAST CANCER; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DRUG POTENTIATION; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; ENHANCER REGION; GENE MUTATION; GENE SILENCING; GENETIC SCREENING; HUMAN; LOSS OF FUNCTION MUTATION; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NEUROBLASTOMA; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE;

ANTINEOPLASTIC AGENTS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; GENETIC TESTING; HUMANS; NEOPLASMS; RNA INTERFERENCE;

EID: 84890816405     PISSN: 0959437X     EISSN: 18790380     Source Type: Journal    
DOI: 10.1016/j.gde.2013.11.007     Document Type: Review

References (43)

1. Misale S., Yaeger R., Hobor S., Scala E., Janakiraman M., Liska D., Valtorta E., Schiavo R., Buscarino M., Siravegna G., Bencardino K., et al. Emergence of kras mutations and acquired resistance to anti-egfr therapy in colorectal cancer. Nature 2012, 486:532-536.
2. Diaz L.A., Williams R.T., Wu J., Kinde I., Hecht J.R., Berlin J., Allen B., Bozic I., Reiter J.G., Nowak M.A., Kinzler K.W., et al. The molecular evolution of acquired resistance to targeted egfr blockade in colorectal cancers. Nature 2012, 486:537-540.
3. Wagle N., Emery C., Berger M.F., Davis M.J., Sawyer A., Pochanard P., Kehoe S.M., Johannessen C.M., Macconaill L.E., Hahn W.C., Meyerson M., et al. Dissecting therapeutic resistance to raf inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011, 29:3085-3096.
4. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., Bergethon K., Shaw A.T., Gettinger S., Cosper A.K., Akhavanfard S., et al. Genotypic and histological evolution of lung cancers acquiring resistance to egfr inhibitors. Sci Transl Med 2011, 3:75ra26.
5. Girotti M.R., Pedersen M., Sanchez-Laorden B., Viros A., Turajlic S., Niculescu-Duvaz D., Zambon A., Sinclair J., Hayes A., Gore M., Lorigan P., et al. Inhibiting egf receptor or src family kinase signaling overcomes braf inhibitor resistance in melanoma. Cancer Discov 2013, 3:158-167.
6. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide rnas mediate rna interference in cultured mammalian cells. Nature 2001, 411:494-498.
7. Echeverri C.J., Beachy P.A., Baum B., Boutros M., Buchholz F., Chanda S.K., Downward J., Ellenberg J., Fraser A.G., Hacohen N., Hahn W.C., et al. Minimizing the risk of reporting false positives in large-scale rnai screens. Nat Methods 2006, 3:777-779.
8. Mendes-Pereira A.M., Sims D., Dexter T., Fenwick K., Assiotis I., Kozarewa I., Mitsopoulos C., Hakas J., Zvelebil M., Lord C.J., Ashworth A. Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad Sci U S A 2012, 109:2730-2735.
9. Iorns E., Turner N.C., Elliott R., Syed N., Garrone O., Gasco M., Tutt A.N., Crook T., Lord C.J., Ashworth A. Identification of cdk10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 2008, 13:91-104.
10. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., Linn S.C., Gonzalez-Angulo A.M., Stemke-Hale K., Hauptmann M., Beijersbergen R.L., et al. A functional genetic approach identifies the pi3k pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
11. Wetterskog D., Shiu K.K., Chong I., Meijer T., Mackay A., Lambros M., Cunningham D., Reis-Filho J.S., Lord C.J., Ashworth A. Identification of novel determinants of resistance to lapatinib in erbb2-amplified cancers. Oncogene 2013, Epub ahead of print.
12. Eichhorn P.J., Gili M., Scaltriti M., Serra V., Guzman M., Nijkamp W., Beijersbergen R.L., Valero V., Seoane J., Bernards R., Baselga J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mtor/phosphatidylinositol 3-kinase inhibitor nvp-bez235. Cancer Res 2008, 68:9221-9230.
13. Huang S., Laoukili J., Epping M.T., Koster J., Holzel M., Westerman B.A., Nijkamp W., Hata A., Asgharzadeh S., Seeger R.C., Versteeg R., et al. Znf423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell 2009, 15:328-340.
14. Holzel M., Huang S., Koster J., Ora I., Lakeman A., Caron H., Nijkamp W., Xie J., Callens T., Asgharzadeh S., Seeger R.C., et al. Nf1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010, 142:218-229.
15. Spreafico A., Tentler J.J., Pitts T.M., Tan A.C., Gregory M.A., Arcaroli J.J., Klauck P.J., McManus M.C., Hansen R.J., Kim J., Micel L.N., et al. Rational combination of a mek inhibitor, selumetinib, and the wnt/calcium pathway modulator, cyclosporin a, in preclinical models of colorectal cancer. Clin Cancer Res 2013, 19:4149-4162.
16. Huang S., Holzel M., Knijnenburg T., Schlicker A., Roepman P., McDermott U., Garnett M., Grernrum W., Sun C., Prahallad A., Groenendijk F.H., et al. Med12 controls the response to multiple cancer drugs through regulation of tgf-beta receptor signaling. Cell 2012, 151:937-950.
17. Brunen D., Willems S.M., Kellner U., Midgley R., Simon I., Bernards R. Tgf-β: an emerging player in drug resistance. Cell Cycle 2013, 12:2960-2968.
18. Kaelin W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev 2005, 5:689-698.
19. Whitehurst A.W., Bodemann B.O., Cardenas J., Ferguson D., Girard L., Peyton M., Minna J.D., Michnoff C., Hao W., Roth M.G., Xie X.J., et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007, 446:815-819.
20. Fotheringham S., Epping M.T., Stimson L., Khan O., Wood V., Pezzella F., Bernards R., La Thangue N.B. Genome-wide loss-of-function screen reveals an important role for the proteasome in hdac inhibitor-induced apoptosis. Cancer Cell 2009, 15:57-66.
21. Liu-Sullivan N., Zhang J., Bakleh A., Marchica J., Li J., Siolas D., Laquerre S., Degenhardt Y.Y., Wooster R., Chang K., Hannon G.F., et al. Pooled shrna screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (plk1). Oncotarget 2011, 2:1254-1264.
22. Zhu Y.X., Tiedemann R., Shi C.X., Yin H., Schmidt J.E., Bruins L.A., Keats J.J., Braggio E., Sereduk C., Mousses S., Stewart A.K. Rnai screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including cdk5. Blood 2011, 117:3847-3857.
23. Gregory M.A., Phang T.L., Neviani P., Alvarez-Calderon F., Eide C.A., O'Hare T., Zaberezhnyy V., Williams R.T., Druker B.J., Perrotti D., Degregori J. Wnt/ca2+/nfat signaling maintains survival of ph+ leukemia cells upon inhibition of bcr-abl. Cancer Cell 2010, 18:74-87.
24. Prahallad A., Sun C., Huang S., Di Nicolantonio F., Salazar R., Zecchin D., Beijersbergen R.L., Bardelli A., Bernards R. Unresponsiveness of colon cancer to braf(v600e) inhibition through feedback activation of egfr. Nature 2012, 483:100-103.
25. Corcoran R.B., Ebi H., Turke A.B., Coffee E.M., Nishino M., Cogdill A.P., Brown R.D., Pelle P.D., Dias-Santagata D., Hung K.E., Flaherty K.T., et al. Egfr-mediated re-activation of mapk signaling contributes to insensitivity of braf mutant colorectal cancers to raf inhibition with vemurafenib. Cancer Discov 2012, 2:227-235.
26. Corcoran R.B., Cheng K.A., Hata A.N., Faber A.C., Ebi H., Coffee E.M., Greninger P., Brown R.D., Godfrey J.T., Cohoon T.J., Song Y., et al. Synthetic lethal interaction of combined bcl-xl and mek inhibition promotes tumor regressions in kras mutant cancer models. Cancer Cell 2013, 23:121-128.
27. Flaherty K.T., Infante J.R., Daud A., Gonzalez R., Kefford R.F., Sosman J., Hamid O., Schuchter L., Cebon J., Ibrahim N., Kudchadkar R., et al. Combined braf and mek inhibition in melanoma with braf v600 mutations. N Engl J Med 2012, 367:1694-1703.
28. Baselga J., Bradbury I., Eidtmann H., Di Cosimo S., de Azambuja E., Aura C., Gomez H., Dinh P., Fauria K., Van Dooren V., Aktan G., et al. Lapatinib with trastuzumab for her2-positive early breast cancer (neoaltto): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379:633-640.
29. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., Martin N.M., et al. Targeting the DNA repair defect in brca mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
30. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M.J., Ashworth A., et al. Inhibition of poly(adp-ribose) polymerase in tumors from brca mutation carriers. N Engl J Med 2009, 361:123-134.
31. Ngo V.N., Davis R.E., Lamy L., Yu X., Zhao H., Lenz G., Lam L.T., Dave S., Yang L., Powell J., Staudt L.M., et al. A loss-of-function rna interference screen for molecular targets in cancer. Nature 2006, 441:106-110.
32. Brough R., Frankum J.R., Sims D., Mackay A., Mendes-Pereira A.M., Bajrami I., Costa-Cabral S., Rafiq R., Ahmad A.S., Cerone M.A., Natrajan R., et al. Functional viability profiles of breast cancer. Cancer Discov 2011, 1:260-273.
33. Martin S.A., Hewish M., Sims D., Lord C.J., Ashworth A. Parallel high-throughput rna interference screens identify pink1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. Cancer Res 2011, 71:1836-1848.
34. Herrera-Abreu M.T., Pearson A., Campbell J., Shnyder S.D., Knowles M.A., Ashworth A., Turner N.C. Parallel rna interference screens identify egfr activation as an escape mechanism in fgfr3 mutant cancer. Cancer Discov 2013.
35. Kumar M.S., Hancock D.C., Molina-Arcas M., Steckel M., East P., Diefenbacher M., Armenteros-Monterroso E., Lassailly F., Matthews N., Nye E., Stamp G., et al. The gata2 transcriptional network is requisite for ras oncogene-driven non-small cell lung cancer. Cell 2012, 149:642-655.
36. Kessler J.D., Kahle K.T., Sun T., Meerbrey K.L., Schlabach M.R., Schmitt E.M., Skinner S.O., Xu Q., Li M.Z., Hartman Z.C., Rao M., et al. A sumoylation-dependent transcriptional subprogram is required for myc-driven tumorigenesis. Science 2012, 335:348-353.
37. Cheung H.W., Cowley G.S., Weir B.A., Boehm J.S., Rusin S., Scott J.A., East A., Ali L.D., Lizotte P.H., Wong T.C., Jiang G., et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A 2011, 108:12372-12377.
38. Carette J.E., Guimaraes C.P., Wuethrich I., Blomen V.A., Varadarajan M., Sun C., Bell G., Yuan B., Muellner M.K., Nijman S.M., Ploegh H.L., et al. Global gene disruption in human cells to assign genes to phenotypes by deep sequencing. Nat Biotechnol 2011, 29:542-546.
39. Pettitt S.J., Rehman F.L., Bajrami I., Brough R., Wallberg F., Kozarewa I., Fenwick K., Assiotis I., Chen L., Campbell J., Lord C.J., et al. A genetic screen using the piggybac transposon in haploid cells identifies parp1 as a mediator of olaparib toxicity. PLoS ONE 2013, 8:e61520.
40. Mali P., Yang L., Esvelt K.M., Aach J., Guell M., DiCarlo J.E., Norville J.E., Church G.M. Rna-guided human genome engineering via cas9. Science 2013, 339:823-826.
41. Scholl C., Frohling S., Dunn I.F., Schinzel A.C., Barbie D.A., Kim S.Y., Silver S.J., Tamayo P., Wadlow R.C., Ramaswamy S., Dohner K., et al. Synthetic lethal interaction between oncogenic kras dependency and stk33 suppression in human cancer cells. Cell 2009, 137:821-834.
42. Babij C., Zhang Y., Kurzeja R.J., Munzli A., Shehabeldin A., Fernando M., Quon K., Kassner P.D., Ruefli-Brasse A.A., Watson V.J., Fajardo F., et al. Stk33 kinase activity is nonessential in kras-dependent cancer cells. Cancer Res 2011, 71:5818-5826.
43. Luo T., Masson K., Jaffe J.D., Silkworth W., Ross N.T., Scherer C.A., Scholl C., Frohling S., Carr S.A., Stern A.M., Schreiber S.L., et al. Stk33 kinase inhibitor brd-8899 has no effect on kras-dependent cancer cell viability. Proc Natl Acad Sci U S A 2012, 109:2860-2865.